Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study

被引：0
|
作者：
Chai, Y. [1 ]
Jiang, M. [1 ]
Liu, J. [1 ]
He, M. [1 ]
Wang, X. [2 ]
Wang, Y. [2 ]
Yang, X. [2 ]
Wang, J. [2 ]
Xu, B. [3 ]
Li, Q. [4 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Med Oncol Dept, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Surg Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Med Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360P
引用
收藏
页码：S327 / S327
页数：1
相关论文
共 50 条
  • [41] Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia
    Lok, Sheau Wen
    De Boer, Richard
    Baron-Hay, Sallt
    Button, Peter
    Devitt, Bianca
    Forster, Benjamin
    Fox, Peter
    Harold, Michael
    Ketheeswaran, Sahisha
    Kichenadasse, Ganessan
    Kiely, Belinda E.
    Marx, Gavin
    Nott, Louise
    Pellegrini, Laura
    Tafreshi, Ali
    Gibbs, Peter
    CANCER RESEARCH, 2022, 82 (04)
  • [42] Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)
    Masuda, N.
    Ohtani, S.
    Takano, T.
    Inoue, K.
    Suzuki, E.
    Nakamura, R.
    Bando, H.
    Ito, Y.
    Ishida, K.
    Yamanaka, T.
    Kuroi, K.
    Yasojima, H.
    Kasai, H.
    Takasuka, T.
    Sakurai, T.
    Kataoka, T. R.
    Morita, S.
    Ohno, S.
    Toi, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
    Ma, Xiangmin
    Zhang, Xiangmei
    Zhou, Xinping
    Ren, Xiaofei
    Ma, Xindi
    Zhang, Weifang
    Yang, Ruiling
    Song, Tao
    Liu, Yunjiang
    MEDICINE, 2022, 101 (40) : E30892
  • [44] Neoadjuvant Chemotherapy with or without Anthracyclines Combined with Trastuzumab and Pertuzumab in HER2-Positive Breast Cancer: A Multicenter Retrospective Study in China
    Zhang, Y.
    Zhou, J.
    Yang, S.
    Li, G.
    Wang, X.
    Bai, L.
    Zhang, S.
    Cao, W.
    Ouyang, T.
    Jiang, Z.
    He, Y.
    Wang, T.
    Fan, Z.
    BREAST, 2025, 80
  • [45] Effect of Weekly Carboplatin and Paclitaxel with Trastuzumab and Pertuzumab (wPCbTP) on Nodal Disease and Surgical Options in HER2-positive Breast Cancer
    Ciambella, Chelsey
    Dizon, Don
    Taneja, Charu
    Graves, Theresa
    Lopresti, Mary
    Sikov, William
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S421 - S422
  • [46] Phase II study of neoadjuvant NALIRIFOX followed by chemoradiation with paclitaxel and carboplatin in locally advanced gastroesophageal cancer
    Yon-Li Wo, Jennifer
    Strickland, Matthew
    Yeap, Beow Y.
    Guan, Zoe
    Keane, Florence
    Roberts, Hannah Johnson
    Morse, Christopher
    Lanuti, Michael
    Mullen, John Thomas
    Sachdeva, Uma
    Auchincloss, Hugh G.
    Mendel, Bailey
    Drapek, Lorraine C.
    Meurer, Jessica
    Blaszkowsky, Lawrence Scott
    Clark, jeffrey William
    Hong, Theodore S.
    Klempner, Samuel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 452 - 452
  • [47] Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer)
    Semiglazov, V.
    Eiermann, W.
    Manikhas, A.
    Bozok, A.
    Lluch, A.
    Tjulandine, S.
    Feyereislova, A.
    Valagussae, P.
    Baselga, J.
    Gianni, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 169 - 170
  • [48] Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia: Interim analysis
    Lok, Sheau Wen
    De Boer, Richard
    Baron-Hay, Sally
    Boyle, Fran
    Button, Peter
    Castles, Belinda
    Devitt, Bianca
    Fox, Peter
    Harold, Michael
    Kichenadasse, Ganessan
    Kiely, Belinda E.
    Marx, Gavin
    Nott, Louise
    Pellegrini, Laura
    Tafreshi, Ali
    Gibbs, Peter
    CANCER RESEARCH, 2020, 80 (04)
  • [49] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Patel, Tejal A.
    Ensor, Joe E.
    Creamer, Sarah L.
    Boone, Toniva
    Rodriguez, Angel A.
    Niravath, Poly A.
    Darcourt, Jorge G.
    Meisel, Jane L.
    Li, Xiaoxian
    Zhao, Jing
    Kuhn, John G.
    Rosato, Roberto R.
    Qian, Wei
    Belcheva, Anna
    Schwartz, Mary R.
    Kaklamani, Virginia G.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [50] Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory breast cancer
    Overmoyer, B. A.
    Regan, M.
    Brugge, J.
    Perou, C. M.
    Nakhlis, F.
    Jennifer, B.
    Heather, J.
    Eren, Y. D.
    Judith, H-B
    Winer, E.
    CANCER RESEARCH, 2013, 73
12345